Mirati Experimental Lung Cancer Drug Shows Favorable Tolerability, Promising Efficacy

Vandana Singh
·1 min read

  • Mirati Therapeutics Inc (NASDAQ: MRTX) announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort of adagrasib combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in previously untreated metastatic lung cancer patients, harboring a KRASG12C mutation.

  • Early data shows that a combination treatment demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate (ORR) of 49%, with a manageable safety profile.

  • Related: Mirati Therapeutics Garners Interest From Large Pharmas Ahead Of Much Awaited Data Next Month.

  • Wall Street analysts called the early results encouraging, Reuters reported, but shares of Mirati were down more than 8%. More trial details will be presented on Wednesday.

  • "We believe the data continue to support the regimen's differentiated positioning relative to standard of care and are far more favorable than that of Lumakras plus (immunotherapy)," a JP Morgan analyst said, referring to Amgen Inc's (NASDAQ: AMGN) drug.

  • Out of seven phase-two trial patients given the adagrasib combination, four (57%) had tumor shrinkage and a disease control rate of 100%.

  • Price Action: MRTX shares traded 9.60% lower at $83.85 during pre-market trading on Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.